2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-169835
    1-Benzyl-APDC 171336-76-8 98%
    1-Benzyl-APDC acts as an agonist for mGluR6, with an EC50 of 20 μM in CHO cells. 1-Benzyl-APDC is a weak antagonist of mGluR2, with an IC50 of 200 μM.
    1-Benzyl-APDC
  • HY-169841
    IHCH-7086 2957888-70-7 98%
    IHCH-7086 is a β-arrestin-biased 5-HT2A serotonin receptor agonist (Ki: 12.59 nM). IHCH-7086 recruits β-arrestin through activation of 5-HT2A receptors, thereby removing hallucinogenic activity. IHCH-7086 improves depression-like behavior in mice without hallucinogenic effects.
    IHCH-7086
  • HY-169845
    Calcium Channel antagonist 6 687568-35-0
    Calcium Channel antagonist 6 (Compound 328) is a highly selective antagonist of voltage-gated calcium channel CaV2.2 with an IC50 value of 0.37 μM. Calcium Channel antagonist 6 inhibits of neuron depolarization-induced Ca2+ influx. Calcium Channel antagonist 6 is promising for research of neuropathic pain.
    Calcium Channel antagonist 6
  • HY-169852
    Doxapram intermediate-1 3192-92-5 98%
    Doxapram intermediate-1 (Compound II) is a pyrrolidinone derivative with pronounced central nervous system (CXS) and respiratory stimulation in the dog usually accompanied by varying degrees of pressor activity.
    Doxapram intermediate-1
  • HY-169907
    Anticancer agent 258 2891984-12-4 98%
    Anticancer agent 258 is an imidazo [1,2-B][1,2,4] triazol derivative. Anticancer agent 258 regulates the activity of nuclear receptors. Anticancer agent 258 has an EC50 of 63 nM against Nurr in N2A cells. Anticancer agent 258 has IC50 of 0.1 pM for Nur77 in HEK293 cells. Anticancer agent 258 can be used in the study of cancer, metabolic diseases and neurological disorders.
    Anticancer agent 258
  • HY-169914
    Igmesine hydrochloride 130152-35-1 98%
    Igmesine hydrochloride (JO 1784) is an orally active σ-receptor ligand capable of blocking the increase in colonic electromechanical activity induced by emotional stress. Igmesine hydrochloride also eliminates the colonic motility stimulation induced by dopamine, as well as the stimulation induced by centrally injected D1 or D2 receptor agonists. Furthermore, Igmesine hydrochloride can block the colonic motility responses induced by corticotropin-releasing factor (CRF) and ES through central cholecystokinin (CCK) release and/or activation of supraspinal CCK pathways.
    Igmesine hydrochloride
  • HY-169950
    NMDA agonist 1 2576586-47-3 98%
    NMDA agonist 1 (compound 42d) is a potent NMDA agonist with a Ki value of 96 nM. NMDA agonist 1 acts as a partial agonist of the GluN1/GluN2B complex with an EC50 value of 78 nM.
    NMDA agonist 1
  • HY-169951
    Lu AF90103 2577196-14-4 98%
    Lu AF90103 (Compound 42e) is a methyl ester prodrug of compound 42d capable of penetrating the blood-brain barrier. Compound 42d acts as a partial agonist of the GluN1/GluN2B complex, exhibiting 24% efficacy, and has an EC50 value of 78 nM. Lu AF90103 plays an important role in neuropsychiatric diseases research.
    Lu AF90103
  • HY-169959
    OTs-PEG3-NHCO-Thalidomide 2716123-18-9 98%
    OTs-PEG3-NHCO-Thalidomide is a ubiquitin E3 ligase and linker for PROTAC α-synuclein degrader 6 (HY-157839), which can be used in research on neurodegenerative diseases.
    OTs-PEG3-NHCO-Thalidomide
  • HY-169962
    hCA I-IN-4 3054159-56-4 98%
    hCA I-IN-4 (Compound 14) is the inhibitor for carbonic anhydrase and cholinesterase, that inhibits hCA I, hCA II, AChE, and BChE with Ki of 29.94 nM, 17.72 nM, 21.21 nM, and 7.65 nMrespectively. hCA I-IN-4 exhibits cytotoxicity in BT-549 with IC50 of 16.59 μM.
    hCA I-IN-4
  • HY-170023
    Samidorphan isoquinoline dioxolane 361525-83-9 98%
    Samidorphan isoquinoline dioxolane (Compound 16) is a cyclazocine analogue with opioid receptor binding properties.
    Samidorphan isoquinoline dioxolane
  • HY-170032
    Oxotremorine 70-22-4 98%
    Oxotremorine is an agonist for mAChR, that activates M1 and M3 acetylcholine receptors. Oxotremorine exhibits nicotine-like effects in drug discrimination experiments in macaques.
    Oxotremorine
  • HY-170033
    3-Carboxamidonaltrexone 421552-35-4 98%
    3-Carboxamidonaltrexone (example 32) is a opioid receptor binding compound with Ki values of 1.9 nM, 110 nM, and 22 nM for μ-opioid receptor, δ-opioid receptor, and K-opioid receptor, respectively.
    3-Carboxamidonaltrexone
  • HY-170053
    4-Hydroxy MPT 763035-03-6 98%
    4-Hydroxy MPT (4-OH-MPT), a serotonergic hallucinogen, is a 5-HT2A and 5-HT2B receptors agonist with EC50 values of 3.82 nM and 3.4 nM, respectively.
    4-Hydroxy MPT
  • HY-17020S
    Miglustat-d9 1883545-56-9 98%
    Miglustat-d9 is the deuterium labeled Miglustat. Miglustat (N-Butyldeoxynojirimycin) is an inhibitor of glucosylceramide synthase, primarily to treat Type I Gaucher disease (GD1).
    Miglustat-d9
  • HY-170236
    nNOS-IN-5 2945955-27-9 98%
    nNOS-IN-5 (Compound 9) is a potent human neuronal NOS (nNOS) inhibitor (Ki = 22 nM). nNOS-IN-5 exhibits excellent selectivity, with a 900-fold preference for human nNOS over human endothelial NOS (eNOS). nNOS-IN-5 can be used for neurodegenerative diseases study, such as Alzheimer's disease and Parkinson’s disease.
    nNOS-IN-5
  • HY-170302
    CMP233 307001-06-5 98%
    CMP233 is a potent antagonist of TRPM4, with the IC50 of 0.15 μM. CMP233 plays an important role in neurodegenerative disorders research.
    CMP233
  • HY-170310
    AP-238 140924-11-4 98%
    AP-238 is a a new synthetic opioid (NSO), and acts as an agonist for μ-opioid receptor (MOR) with an EC50 of 248 nM. AP-238 exhibits analgesic activity.
    AP-238
  • HY-170325
    17alpha-Hydroxywithanolide D 98%
    17alpha-Hydroxywithanolide D is the allosteric modulator for NMDA receptor with an IC50 of 44.24 nM. 17alpha-Hydroxywithanolide D exhibits neuroprotective activity and can be used in research of Alzheimer's disease disease.
    17alpha-Hydroxywithanolide D
  • HY-17032A
    Indeloxazine hydrochloride 65043-22-3 98%
    Indeloxazine hydrochloride is a 5-HT receptor and norepinephrine (NE) reuptake inhibitor. Indeloxazine hydrochloride is an antidepressant and cerebral activator.
    Indeloxazine hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity